2. Search Result
Search Result
Results for "

VcMMAE

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

5

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15575
    VcMMAE
    65+ Cited Publications

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
    VcMMAE
  • HY-164835
    VcMMAE-Deruxtecan

    SMP-54418

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Topoisomerase Cancer
    VcMMAE-Deruxtecan is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
    VcMMAE-Deruxtecan
  • HY-15575G
    VcMMAE

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE

    		 Drug-Linker Conjugates for ADC Cancer
    VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .
    VcMMAE
  • HY-15575S
    VcMMAE-d8

    MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
    VcMMAE-d8
  • HY-164153
    ADC Control Human IgG1-vcMMAE

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
    ADC Control Human IgG1-vcMMAE
  • HY-145627
    Ozuriftamab vedotin

    BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
    Ozuriftamab vedotin
  • HY-78738
    MC-Val-Cit-PAB

    		ADC Linker Cancer
    MC-Val-Cit-PAB is a cleavable ADC Linker that forms part of VcMMAE (HY-15575). VcMMAE is Drug-Linker Conjugates for ADCs. The ADC Cytotoxin in VcMMAE is MMAE, a tubulin polymerization inhibitor.
    MC-Val-Cit-PAB
  • HY-164837
    VcMMAE-Eribulin

    SMP13432

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). VcMMAE-Eribulin can be used for ADC synthesis.
    VcMMAE-Eribulin
  • HY-171683
    Anti-CCL2 (Carlumab)-VcMMAE

    		Antibody-Drug Conjugates (ADCs) CCR Microtubule/Tubulin Apoptosis Cancer
    Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research .
    Anti-CCL2 (Carlumab)-VcMMAE
  • HY-171821
    PF-08046054

    SGN-PDL1V

    		 Antibody-Drug Conjugates (ADCs) PD-1/PD-L1 Microtubule/Tubulin Cancer
    PF-08046054 (SGN-PDL1V) is a PD-L1-directed antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to the vedotin drug-linker, VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors .
    PF-08046054
  • HY-P99107A
    Brentuximab vedotin (solution)

    		Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma .
    Brentuximab vedotin (solution)
  • HY-141604
    Glembatumumab vedotin
    1 Publications Verification

    CDX-011; CR011-VcMMAE

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
    Glembatumumab vedotin
  • HY-P99595
    Sirtratumab vedotin

    AGS15E; ASG-15ME; 1VcMMAE

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
    Sirtratumab vedotin
  • HY-141602
    Pinatuzumab vedotin

    anti-CD22-vc-MMAE; DCDT2980S

    		 Antibody-Drug Conjugates (ADCs) CD22 Microtubule/Tubulin Cancer
    Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities .
    Pinatuzumab vedotin
  • HY-171135
    Cetuximab MMAE

    		Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
    Cetuximab MMAE
  • HY-78738G
    MC-Val-Cit-PAB

    		ADC Linker Cancer
    MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
    MC-Val-Cit-PAB
  • HY-171265
    MRG003

    		Antibody-Drug Conjugates (ADCs) EGFR Others
    MRG003 is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
    MRG003
  • HY-132253
    Polatuzumab vedotin

    		Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin
  • HY-152963
    Tisotumab vedotin

    		Antibody-Drug Conjugates (ADCs) Inflammation/Immunology Cancer
    Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
    Tisotumab vedotin
  • HY-132253A
    Polatuzumab vedotin (solution)

    		Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin (solution)
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv
  • HY-171754
    LM-305

    		Antibody-Drug Conjugates (ADCs) Cancer
    LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
    LM-305
  • HY-171572
    Atezolizumab-MMAE

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Apoptosis Inflammation/Immunology Cancer
    Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
    Atezolizumab-MMAE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: